Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17326569 | 0.89 | RXRA (0.50) | RXRASMN1; SMN2THRBHCAR3HSD17B10 | |
| SCHEMBL17326600 | 0.86 | RXRA (0.61) | RXRASMN1; SMN2THRBHCAR3PTPN11 | |
| SCHEMBL17326618 | 0.86 | RXRA (0.50) | RXRASMN1; SMN2THRBHSD17B10 | |
| SCHEMBL17326601 | 0.79 | RXRA (0.50) | RXRAPTPN11RXRBRXRG | |
| SCHEMBL17326802 | 0.77 | RXRA (0.48) | RXRAPTPN11RXRBRXRG | |
| SCHEMBL17326555 | 0.75 | RXRA (0.47) | RXRASMN1; SMN2THRBHCAR3HSD17B10 | |
| SCHEMBL17326619 | 0.73 | RXRA (0.47) | RXRASMN1; SMN2THRBHSD17B10RXRB | |
| SCHEMBL18950565 | 0.71 | HSD17B10 (0.70) | RXRASMN1; SMN2THRBHCAR3HSD17B10 | |
| SCHEMBL17325983 | 0.68 | RXRA (1.00) | RXRARXRBRXRG | |
| SCHEMBL17326801 | 0.67 | RXRA (0.41) | RXRASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015187850-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF OCULAR DISORDERS | DUKE UNIVERSITY (US) | 2015-12-10 | — | — | WO | disclosed |